Absorption is rapid, with mean Avoid or substitute another drug for these medications when possible
Saquinavir: See the prescribing information for saquinavir and monitor for potential saquinavir toxicities
• See full prescribing information for alternative administration PREVACID PREVACID Pharmaceuticals America Inc
2 , 2
heartburn) and / or ulcer-like symptoms (e
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide
Atazanavir: See prescribing information for atazanavir for dosing information
Evaluate for loss of therapeutic effect if medication must be coadministered
Description for Prevacid
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide
Refer to full prescribing information for the oral formulations of PREVACID
Its empirical formula is C
S with a molecular weight of 369
Prevacid is a brand (trade) name for lansoprazole
Approval: 1995 -----RECENT MAJOR CHANGES----- WARNINGS AND PRECAUTIONS Concomitant Use of PREVACID with Methotrexate (5
Controlled studies did not extend beyond indicated duration
for up to 8 weeks No additional information
Lansoprazole is freely soluble in dimethylformamide; soluble in methanol; sparingly soluble in ethanol; slightly soluble in ethyl acetate, dichloromethane and acetonitrile; very slightly soluble in ether; and practically insoluble in hexane and water
Place the tablet on the tongue and allow it to disintegrate, with or without water, until the particles can be swallowed
• Place the tablet on the tongue and allow it to disintegrate, with or without water, until the particles can be swallowed
• See full prescribing information for alternative administration • See full prescribing information for alternative administration options
H
• Place the tablet on the tongue and allow it to disintegrate, with or without water, until the particles can be swallowed
• See full prescribing information for alternative administration curves (AUCs) of lansoprazole were approximately proportional to the administered dose
PREVACID SoluTab • Should not be broken or cut
See full prescribing information Tablets > 30 kg GERD Symptomatic GERD These highlights do not include all the information needed to use for: (lansoprazole) Delayed-Release Capsules Prescription lansoprazole is used to treat the damage from GERD in adults and children 1 year of age and older
9 5
Approval: 1995 (lansoprazole) See full prescribing information for alternative administration options
See full prescribing information for alternative administration options
Place the tablet on the tongue and allow it to disintegrate, with or without water, until the particles can be swallowed
Dual therapy: The recommended adult oral dose is 1 gram AMOXIL and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days
3) Administration Instructions (2
R- and S-enantiomers)
1
Approval: 1995 See full prescribing information for complete dosing information for PREVACID and PREVACID SoluTab by indication and age group and dosage adjustment in patients with severe hepatic impairment
Full or standard dose
PRILOSEC (omeprazole) Delayed-Release Capsules and PRILOSEC (omeprazole magnesium) For Delayed-Release Oral Suspension
1 Duodenal
It is not known whether lansoprazole is excreted in human milk
2
CYP2C19 or CYP3A4 Inhibitors: Clinical Impact: Increased exposure of lansoprazole is expected when used concomitantly with strong inhibitors (see CLINICAL PHARMACOLOGY)
Dual Therapy: PREVACID/amoxicillin PREVACID in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H
See full prescribing information for PREVACID and PREVACID SOLUTAB
PRILOSEC is supplied as delayed-release capsules for oral administration
S
PREVACID (lansoprazole) delayed-release capsules Initial U
PREVACID (lansoprazole) delayed-release capsules, for oral use PREVACID SOLUTAB (lansoprazole) delayed-release orally disintegrating tablets Initial U
Welcome to bumps
pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
Medscape - Peptic ulcer disease dosing for Prevacid, Prevacid Solu Tab (lansoprazole), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and
Indication
MEDICATION GUIDE PREVACID (prev-a-sid) (lansoprazole) delayed-release capsules, for oral use and PREVACID SoluTab (prev-a-sid sol-u-tab) (lansoprazole) delayed-release
O
Prevacid (lansoprazole) is a proton pump inhibitor (PPI) used to treat and prevent stomach and intestinal ulcers, erosive esophagitis (damage to the esophagus
1
The safety and efficacy of
pylori
Prevacid (lansoprazole) works by reducing the production of stomach acid and it does this by irreversibly blocking the actions of an enzyme responsible for acid production, called H+/K+ ATPase (also known as the gastric proton pump)
For more information, call 1-800-206-7821
• See full prescribing information for alternative administration options
Atazanavir: See prescribing information for atazanavir for dosing information
PREVACID®, PREVACID® FasTab Product Monograph Page 68 of 80 (lansoprazole delayed-release capsules, lansoprazole delayed-release tablets) Non-medicinal ingredients: colloidal silicon dioxide, D&C Red No
Prescription lansoprazole is used to allow the esophagus to heal and prevent further damage to the esophagus in adults with GERD
4 Dosing in Renal
3 Maintenance of Healed Duodenal Ulcers
• See full prescribing information for alternative administration See full prescribing information for alternative administration options
See full prescribing information for alternative administration options
2 These highlights do not include all the information needed to use for: PREVACID (lansoprazole) Delayed-Release Capsules PREVACID SoluTab (lansoprazole) Delayed-Release Orally
pylori Eradication to reduce the risk of duodenal ulcer 30 mg w/ amoxicillin 1 g (or metronidazole 400 mg) & clarithromycin 250-500 mg, all bid (every 12 hr) for 7 days
Tablet Disintegrating, Delayed Release
Approval: 1995 See full prescribing information for complete dosing information for PREVACID and PREVACID SoluTab by indication and age group and dosage adjustment in patients with severe hepatic impairment
Lansoprazole doses in BNF may differ from those in product literature
Should not be broken or cut
CYP2C19 or CYP3A4 Inhibitors: Clinical Impact: Increased exposure of lansoprazole is expected when used concomitantly with strong inhibitors (see CLINICAL PHARMACOLOGY)